HomeAI · summaries
Storia in 3 fonti
Otsuka touts new IgAN evidence as it seeks full approval for Voyxact
Otsuka's Voyxact preserved kidney function over 12 months in IgA nephropathy patients, new eGFR data show, as the company pursues full FDA approval.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and…
- ·
statnews.com
Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.
